FIELD: medicine. SUBSTANCE: method involves carrying out reperfusion with solution containing 185-240 mM of sodium after applying cardioplegic solutions with calcium antagonists after operation. Sodium concentration violating the mentioned boundaries makes heart contractility change for the worse. EFFECT: enhanced effectiveness of treatment. 1 dwg, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
CRYSTALLOID CARDIOPLEGIC SOLUTION | 2009 |
|
RU2423135C2 |
"INFUSOL" CARDIOPLEGIC SOLUTION | 2002 |
|
RU2226093C1 |
METHOD FOR PROTECTING HEART FROM ISCHEMIA UNDER EXPERIMENTAL CONDITIONS | 1996 |
|
RU2144825C1 |
METHOD FOR CARDIOPLEGIC ARREST (VERSIONS) | 2015 |
|
RU2571058C1 |
MEASURING METHOD OF CARDIOMIOCYTE SWELLING OF WHOLE HEART, USED WHEN Ca IS REMOVED FROM EXTRACELLULAR MEDIUM DURING EXPERIMENT | 2006 |
|
RU2368956C2 |
CRYSTALLOID CARDIOPLEGIC SOLUTIONS, CONTAINING DODECAPEPTIDES (VERSIONS) | 2013 |
|
RU2549470C1 |
CARDIOPLEGIA AGENT (VERSIONS) | 2014 |
|
RU2568911C1 |
METHOD TO PREVENT AFTEREFFECTS AND COMPLICATIONS OF INDUCED CARDIAC ISCHEMIA | 1993 |
|
RU2083219C1 |
METHOD OF HEARTBEAT RECOVERY FOLLOWING DIASTOLIC ARREST IN EXPERIMENT | 2010 |
|
RU2424582C1 |
METHOD FOR PREVENTING REPERFUSION MYOCARDIAL DAMAGE IN CONGENITAL HEART DISEASE SURGERY | 2019 |
|
RU2718308C1 |
Authors
Dates
1999-07-27—Published
1996-10-03—Filed